Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?

Campbell’s shares are down ~41% YTD through March 19, pushing its dividend yield to 7.4% and leaving a forward P/E of 9 (five-year avg 14); the company cites inflation, tempered growth and a costly 2018 Snyder’s‑Lance deal but retains strong brand shares. Healthpeak (DOC) is down ~7% over the year, yielding 6.9%, is spinning off Janus Living (Healthpeak keeps majority) and maintains ~700 medical outpatient and lab properties. Kraft Heinz fell ~22% over the past year, yielding 7.4%, has a forward P/E of 10.6 (five-year avg 12.2), is investing ~$600M to refresh brands, and has new CEO Steve Cahillane focused on returning to profitable growth.

Analysis

Campbell’s is at a classic operating-turnaround inflection where brand equity gives pricing optionality but legacy M&A and cost structure limit free-cash-flow flexibility; the second-order effect is that any continued margin pressure will force tougher SKU rationalization, which benefits rivals with fresher innovation pipelines and faster supply-chain adaptability. Expect shelf-space contests to intensify: retailers will favor SKUs with higher velocity and lower promotional drag, so brands that can convert liquid meal occasions (direct-to-consumer/meal-replacement formats) will steal share from slower-moving snack lines over 6–18 months.

Healthpeak’s corporate action (majority-owned spin) is a liquidity and governance lever more than an operational one — if the market treats the spin as a true unlock, the parent’s discount should compress quickly, but Healthpeak retains downside exposure to senior-living operator credit and cyclical lab demand. Importantly, lab and outpatient real estate performance is tightly correlated to biotech funding cycles; a pullback in VC or pharma capex would show up as higher vacancy and lower rental growth with a 9–18 month lag.

Kraft Heinz’s near-term trajectory will be decided by allocation choices: heavy brand refresh spending can reaccelerate growth only if paired with distribution and category shifts that materially lift velocity; otherwise elevated marketing budgets become recurring cost inflation undercutting the dividend safety narrative. Across all three names, the dominant tail risks are input-cost stickiness and a macro-driven drop in discretionary consumption that would synchronously pressure margins and FCF, reversing any near-term valuation catch-up within a single earnings season.

Key Decisions for Investors

• Long CPB (equity) — starter position = 20% of target allocation now, average down on any >10% intra-quarter weakness; target 20–30% total return over 9–12 months as cost actions and SKU rationalization flow through. Hedge with a 6–12 month 10% OTM put for defined downside (keeps risk / premium predictable).
• Pair trade: Long DOC (equity) / Short broad lodging or discretionary REIT exposure (equal $ notional) — hold 12–18 months. Rationale: spin-offs and stable outpatient cashflows should re-rate healthcare-specialty REITs vs cyclicals; cut position if REIT cap rates widen by 150–200bps or if Janus spin terms change materially.
• Relative-value pair: Long CPB / Short KHC (equal $ notional) — 6–12 month trade to isolate execution differences in brand refresh spend. Target 15–25% relative outperformance. Stop-loss: close if both names move against the pair by >20% in one month (signals macro shock).
• Defined-risk bearish on KHC: buy a 9–12 month put spread (15%–5% OTM) sized to 5–10% of portfolio — rationale: prevents open-ended short gamma while expressing view that incremental marketing spend may not restore velocity. Take profits if implied vol cheapens by >30% or the company reports two sequential quarters of accelerating organic volume growth.